Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production
Evidence that ADP Potentiates Platelet Secretion Independently of the Formation of Large Platelet Aggregates and Thromboxane A2 Production
Marco Cattaneo
1
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hopsital, University of Milano, Italy;
,
Rossana Lombardi
1
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hopsital, University of Milano, Italy;
,
Maddalena L Zighetti
1
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hopsital, University of Milano, Italy;
,
Christian Gachet
2
INSERM U.311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Philippe Ohlmann
2
INSERM U.311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Jean-Pierre Cazenave
2
INSERM U.311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Pier Mannuccio Mannucci
1
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hopsital, University of Milano, Italy;
By the term “Primary Secretion Defect” (PSD), we mean a common heterogeneous group of congenital defects of platelet secretion, characterized by a normal primary wave of platelet aggregation induced by ADP and other agonists, a normal concentration of platelet granule contents, and normal production of thromboxane A2. The biochemical abnormalities responsible for PSD are not well known. Since a secretion defect similar to PSD is found in platelets that are severely deficient of binding sites for the ADP analogue 2MeS-ADP and do not aggregate in response to ADP, we tested the hypothesis that PSD platelets have moderately decreased 2MeS-ADP binding sites, which may be sufficient for normal ADP-induced aggregation but not for potentiating platelet secretion. The specific binding of [33P]2MeS-ADP to platelets from 3 PSD patients (347,443 and 490 sites/platelet; KD 2.8-3.9 nM) was lower than to platelets from 24 normal subjects (647 [530-1102]; KD = 3.8 [2.3-7.3]) (median [range]). Normal values were found in a fourth PSD patient (710; KD 3.7). The degree of inhibition of PGE1- induced cAMP increase by 0.1 |μM ADP was lower in patients than in controls. The secretion induced by the endoperoxide analogue U46619 from normal, acetylsalicylic acid-treated platelets under conditions that prevented the formation of large aggregates was potentiated by 1 fimol/1 ADP and inhibited by apyrase. These findings indicate that a partial deficiency of the platelet ADP receptor(s) might be responsible for the defect of platelet secretion in some PSD patients and that ADP potentiates platelet secretion independently of the formation of large aggregates and thromboxane A2 production.
References
1
Rao AK.
Congenital disorders of platelet function. In: Platelets in Health and Disease.
Colman RW,
Rao AK.
eds.
Hematol/Oncol Clin North Am. 1990. 04. 65-82
6
Hardisty RM,
Machin SJ,
Nokes TJC,
Rink TJ,
Smith SW.
A new congenital defect of platelet secretion: Impaired responsiveness of the platelets to cytoplasmic free calcium. Br J Haematol 1983; 53: 543-557
7
Cattaneo M,
Lecchi A,
Randi AM,
McGregor JL,
Mannucci PM.
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-2796
8
Gachet C,
Cattaneo M,
Ohlmann P,
hechler B,
Lecchi A,
Chevalier J,
Cassel D,
Mannucci PM,
Cazenave J-P.
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-444
11
Nurden P,
Savi P,
Heilmann E,
Bihour C,
Herbert J-M,
Maffrand J-P,
Nurden A.
An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein Ilb-IIIa complex function. J Clin Invest 1995; 95: 1612-1622
13
Lages B,
Malmsetn C,
Weiss HJ.
Samuelsson B: Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-552
14
Hirata T,
Kakizuka A,
Ushikubi F,
Fuse I,
Okuma M,
Narumiya S.
Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-1667
20
Cattaneo M,
Bettega D,
Lombardi R,
Lecchi A,
Mannucci PM.
Sustained correction of the bleeding time in an afibrinogenemic patient after infusion of fresh frozen plasma. Br J Haematol 1992; 82: 388-390
24
Mustard JF,
Perry DW,
Kinlough-Rathbone RL,
Packham MA.
Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-65